Doug Doerfler is the former CEO of MaxCyte, Inc., a biotechnology company he led from March 2017 until December 2023. With an MBA from the Wharton School, University of Pennsylvania, he has a solid background in the industry. Under his...
Doug Doerfler is the former CEO of MaxCyte, Inc., a biotechnology company he led from March 2017 until December 2023. With an MBA from the Wharton School, University of Pennsylvania, he has a solid background in the industry. Under his leadership, MaxCyte focused on cell therapy and biotechnology solutions that have significantly impacted healthcare. Doerfler's strategy emphasized cash compensation and performance-based bonuses. In 2023, his total compensation hit about $3.14 million, driven by a base salary and performance metrics including revenue and product development targets. Interestingly, he also made major stock option grants totaling 400,000 shares in 2023, highlighting his commitment to the company's growth and shareholder value. His reported holdings once peaked at over $8.61 million in value in late 2021, showing that he has skin in the game. Apart from that, he structured his retirement with 18 months of salary as a transition agreement, aiming for a smooth handover to his successor. Doug's tenure included pivotal phases for MaxCyte, making him a significant figure in the biotech arena.